Leap Investments’s Fate Therapeutics FATE Stock Holding History

Leap Investments’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-25,100	Closed	-$390K	–	470
2019 Q3	$390K	Buy	+25,100	New	+$481K	0.19%	190

Other funds holding FATE

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Grosvenor Holdings Chicago, Illinois $512M AUM 19.57% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Leap Investments's FATE Position: Q4 2019 in Review

Leap Investments sold out of Fate Therapeutics (FATE) in Q4 2019, closing a stake of 25,100 shares — an estimated $390K sold.

Leap Investments first reported a position in FATE in Q3 2019 and held it in 1 quarter. The position peaked at $390K in Q3 2019. 147 funds tracked by Wall St. Rank hold FATE as of Q4 2019.

Leap Investments reported no remaining Fate Therapeutics position as of Q4 2019 after selling out during the quarter.
Leap Investments sold 25,100 Fate Therapeutics shares in Q4 2019, an estimated $390K.
Leap Investments first reported a position in Fate Therapeutics in Q3 2019 and held it in 1 quarter.
Leap Investments's Fate Therapeutics position peaked at $390K in Q3 2019.
147 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2019.

Based on Leap Investments's 13F filing for Q4 2019, filed 14 Feb 2020.